Developing novel devices for the treatment of Dry Eye Disease and Dry Mouth (Xerostomia),
and novel medicines for the treatment of cystic fibrosis and, ultimately, COPD.
Lamellar Biomedical Ltd
Bellshill, United Kingdom ML4 3NJ
Tel: +44 (0) 1698 748 832
Fax: +44 (0) 1698 849 500
Lamellar Biomedical Ltd’s mission is to research, develop and commercialise novel healthcare products based on the mimicry or modification of the lamellar body secretory system.
Our proprietary Lamellasomes™ technology provides the platform to develop novel, first-in-class medicinal and medical device products to treat the unmet or poorly met therapeutic needs of patients with certain ophthalmic, respiratory, cardiovascular, immunological, dermatological, conditions as well bacterially caused infectious diseases and conditions in the supportive care arena resulting from radiation based therapy for cancer.
Lamellasomes™ are the synthetic mimetics of vesicles found in nature, called lamellar bodies. Lamellar bodies manage the internal interfaces between human tissues also, the interfaces between tissues and the external environment, as in the lungs, eyes and mouth.
Deficits of lamellar bodies are indicated in a range of diseases, including dry mouth, dry eye and many serious progressive respiratory conditions, including Cystic Fibrosis (CF) and Chronic Obstructive Pulmonary Disease (COPD).
Artist's Illustration of Lamellasome™ multi-lamellar vesicles.
Our lead LamellasomesTM candidate, LMS-611 has a 3D microstructure and biophysical properties essentially identical to those of a natural lamellar body. The mode of action of LMS-611 is biophysical and not pharmcological.
Initially, development will focus on treatments for the two device opportunites of Radiotherapy-Induced Xerostomia (RIX), commonly known as Dry Mouth in Head and Neck Cancer patients, and Dry Eye Disease. Longer term, the respiratory diseases of Cystic Fibrosis and, later COPD can be targeted.